查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1509675

医药品受託製造的全球市场的评估:各类服务，各剂型，各终端用户，各地区，机会，预测(2017年～2031年)

Pharmaceutical Contract Manufacturing Market Assessment, By Service, By Dosage Form, By End-user, By Region, Opportunities and Forecast, 2017-2031F
出版日期: | 出版商: Market Xcel - Markets and Data | 英文 230 Pages | 商品交期: 3-5个工作天内

价格

全球药品合约製造市场规模预计将从 2023 年的 2070.6 亿美元增至 2031 年的 3576.3 亿美元，预计 2024-2031 年的复合年增长率为 7.07%。製药业的快速扩张、仿製药投资的增加、技术进步、成功的併购等是市场的主要成长动力。

全球各地区市场的扩张得到了慢性病、残疾和传染病病例数量不断增加的支持。根据世界卫生组织 (WHO) 估计，心血管疾病是导致死亡的主要原因之一，每年约导致 1,790 万人死亡。此类慢性疾病的增加增加了对各种治疗解决方案的需求，以有效治疗和管理其症状，为市场提供了利润丰厚的成长机会。这是因为药品生产过程需要专门的设施和设备，而建立药品生产设施往往耗时且经济负担重。因此，公司依靠合约製药公司来满足对治疗药物不断增长的需求。

製药合约製造公司提供的广泛优势，例如节省时间、提高成本效率、提高灵活性和合规性优势，也支持了市场成长。另一方面，增加合作伙伴关係和收购也支持市场扩张。 2024 年 6 月，Great Point Partners, LLC 收购了 Lyocontract GmbH。此次收购将有助于 Lyocontract 扩大其产品组合併扩大其全球足迹。 Great Point 的资本实力和 Lyocontract 的合约製造能力的结合将使两家公司能够提供高品质的产品。

医药产业扩张带动市场需求

未来几年製药业的快速扩张预计将推动全球製药合约製造市场的成长。根据欧洲製药工业联合会估计，2023年北美将占全球药品销售额的53.3%，欧洲将占22.7%。由于药品合约製造有助于优化营运成本，预计这一增长将有助于扩大市场。对药品的需求不断增长，导致公司依赖合约製造公司提供灵活的测试、二级包装组装、製造和初级包装方法。这为未来几年的市场提供了有利的成长机会。

此外，重磅药品和生物製品的到期日增加预计也将推动市场扩张。这些到期预计将增加对重磅药物的仿製药的需求，这预计将增加对合约药品製造的需求，以满足这种增加的需求。这是因为製药公司专注于开发新疗法，并且更愿意将药品生产外包给合约製造组织。另一方面，世界各地慢性病威胁的不断上升也为市场创造了利润丰厚的成长机会。慢性病的增加预计将增加对各种治疗解决方案的需求，从而导致合约药品製造的需求增加。

慢性病的增加支持市场扩张

由于世界不同地区的疾病负担不断增加，对治疗各种慢性疾病的有效疗法的需求不断增加。根据美国癌症协会预测，2024年美国将新增2,001,140例癌症相关病例，611,720例死亡病例。癌症患者数量的增加将增加对癌症治疗药物的需求并支持市场成长。此外，加强各监管机构、研究机构和製药公司之间的合作，以加速药物开发进程并促进创新，同时确保病患安全，也预计将带来机会。此外，多家公司正在投资合约开发和生产设施，以满足癌症药物不断增长的需求。 2022 年 6 月，默克宣布在美国威斯康辛州开设一座占地 70,000 平方英尺的新工厂，将高活性药物成分的产能提高一倍，以满足日益增长的癌症治疗需求。

本报告提供全球医药品受託製造市场相关调查分析，提供市场规模与预测，市场动态，主要企业的形势及预测等资讯。

目录

第1章 调查手法

第2章 计划的范围和定义

第3章 摘要整理

第4章 全球医药品受託製造市场预测(2017年～2031年)

  • 市场规模与预测
    • 金额
  • 各类服务
    • 医药品製造服务
    • 生物製药製造服务
    • 医药品开发服务
  • 各剂型
    • 口服固态剂
    • 口服液剂
    • 液剂
    • 非口服
    • 其他
  • 各终端用户
    • 大型製药企业
    • 中小製药企业
    • 学名药企业
    • 其他
  • 各地区
    • 北美
    • 南美
    • 欧洲
    • 亚太地区
    • 中东·非洲
  • 市场占有率:各企业(2023年)

第5章 全球医药品受託製造市场预测:各地区(2017年～2031年)

  • 北美
    • 市场规模与预测
    • 各类服务
    • 各剂型
    • 各终端用户
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 法国
    • 义大利
    • 英国
    • 俄罗斯
    • 荷兰
    • 西班牙
    • 土耳其
    • 波兰
  • 亚太地区
    • 印度
    • 中国
    • 日本
    • 澳洲
    • 越南
    • 韩国
    • 印尼
    • 菲律宾
  • 南美
    • 巴西
    • 阿根廷
  • 中东·非洲
    • 沙乌地阿拉伯
    • 阿拉伯联合大公国
    • 南非

第6章 市场製图(2023年)

  • 各类服务
  • 各剂型
  • 各终端用户
  • 各地区

第7章 宏观环境和产业结构

  • 供需分析
  • 进口出口分析
  • 价值链分析
  • PESTEL分析
  • 波特的五力分析

第8章 市场动态

  • 成长促进因素
  • 阻碍成长的要素(课题，阻碍因素)

第9章 法规结构和革新

  • 专利形势
  • 法规当局的认证
  • 革新/新技术

第10章 主要企业的形势

  • 市场领导者前五名公司的竞争矩阵
  • 市场领导者前五名公司的市场收益的分析(2023年)
  • 合併和收购/合资企业(如果适用)
  • SWOT分析(市场5企业)
  • 专利分析(如果适用)

第11章 价格分析

第12章 案例研究

第13章 主要企业预测

  • Thermo Fisher Scientific Inc.
  • Abbvie Inc.
  • Lonza Group Ltd.
  • Boehringer Ingelheim International GmbH
  • Catalent, Inc.
  • Pfizer, Inc.
  • Evonik Industries AG
  • Dr. Reddy's Laboratories Ltd.
  • Jubilant Pharmova Limited
  • Recipharm AB

第14章 策略性推荐

第15章 本公司相关资料，免责声明

Product Code: MX11556

Global pharmaceutical contract manufacturing market is projected to witness a CAGR of 7.07% during the forecast period 2024-2031F, growing from USD 207.06 billion in 2023 to USD 357.63 billion in 2031F. The rapid expansion of the pharmaceutical sector, increasing investments in generics, technological advancements, and successful mergers and acquisitions are some of the major drivers that are expected to aid the growth of the market.

The expansion of the market in various regions across the globe is supported by the rise in the cases of chronic diseases and disorders and infectious diseases as they propel the requirement for pharmaceutical products. According to estimates from the World Health Organization (WHO), cardiovascular diseases are one of the leading causes of death, killing approximately 17.9 million individuals every year. The augmentation of such chronic diseases will bolster the requirement for various therapeutic solutions in order to effectively treat and manage the conditions, thus providing lucrative growth opportunities to the market. This is because the drug production process requires specialized facilities and equipment, and the process of setting up a pharmaceutical production facility can often be time-consuming and economically draining. Therefore, various companies rely on pharmaceutical contract manufacturing companies to meet the growing demand for therapeutic drugs.

The growth of the market is also supported by the wide range of benefits offered by pharmaceutical contract manufacturers, including reduced time, cost efficiency, increased flexibility, and compliance benefits. Meanwhile, the increasing partnerships and acquisitions are also supporting the expansion of the market. In June 2024, Great Point Partners, LLC acquired Lyocontract GmbH. The acquisition will aid the latter in broadening their product offerings and expanding their global footprint. The capital resources of Great Point combined with the contract manufacturing capabilities of Lyocontract will allow both companies to deliver high-quality products.

Expansion of the Pharmaceutical Sector Boosts Market Demand

The rapid expansion of the pharmaceutical sector in the coming years is expected to bolster the global pharmaceutical contract manufacturing market growth. The European Federation of Pharmaceutical Industries and Association estimates that North America accounted for 53.3% of global pharmaceutical sales in 2023, and Europe accounted for 22.7% of the sales. This increase is expected to aid the expansion of the market as pharmaceutical contract manufacturing aids the optimization of operational expenses. Due to the rising demand for pharmaceutical products, various companies rely on contract manufacturing companies as they provide an agile approach for testing, assembling secondary packaging, manufacturing, and primary packaging. Thus, providing lucrative growth opportunities to the market in the coming years.

Additionally, the increasing expiration of blockbuster drugs and biologics is also expected to aid the expansion of the market. Due to this expiration, the demand for generics of blockbuster drugs is anticipated to rise, which in turn is expected to propel the demand for pharmaceutical contract manufacturing to meet this rising demand. This is because pharmaceutical companies are focused on developing novel therapeutic solutions and prefer outsourcing drug manufacturing to contract manufacturing organizations. Meanwhile, the growing threat of chronic diseases in different regions across the globe is also providing lucrative growth opportunities to the market. The increasing cases of chronic diseases are anticipated to bolster the requirement for various therapeutic solutions, which in turn is expected to augment the requirement for pharmaceutical contract manufacturing.

Increasing Prevalence of Chronic Diseases Supports Market Expansion

The rising requirement for effective therapies for treating various chronic diseases can be attributed to the growing burden of diseases in various regions across the globe. The American Cancer Society estimates that 2,001,140 new cases and 611,720 deaths related to cancer are expected to occur in 2024 in the United States. This increase in the number of cancer cases will augment the demand for oncology drugs, boosting the growth of the market. Furthermore, rising collaborations between various regulatory entities, research institutions, and pharmaceutical companies to expedite the drug development processes and foster innovation while ensuring the safety of the patients are also expected to offer lucrative growth opportunities to the market. Additionally, various companies are also investing in contract development and manufacturing facilities to address the rising demand for cancer therapies. In June 2022, Merck KGaA announced the opening of their new 70,000 square feet facility in Wisconsin, United States, to double the production capacity of their high-potency active pharmaceutical ingredients to meet the growing requirement of cancer therapies.

North America Expected to Account for Significant Market Share

The growth of the market in North America is supported by the rising requirement for generics, the expansion of the aging population, increasing cases of chronic diseases, and the strong presence of key market players in the region. The increasing prevalence of various chronic diseases and disorders, such as diabetes and cancer, in the region is bolstering the requirement for effective drugs for treating these conditions. According to estimates from the National Institute of Diabetes and Digestive and Kidney Diseases, approximately 29.7 million individuals of all ages, roughly 8.9% of the population, have been diagnosed with diabetes. The increasing cases of such conditions are propelling the requirement for effective drugs for their management and treatment, which, in turn, is augmenting the market demand.

Generic Pharmaceutical Companies are Expected to Witness Growth

The generic pharmaceutical companies are expected to witness significant growth in the coming years. This growth of the segment can be attributed to the expiration of branded drugs and the increasing requirement for generic drugs. The increasing requirement for generics can be attributed to the growing awareness of their potential to enhance healthcare accessibility by offering economically efficient alternatives to expensive biological therapies. According to estimates from the Association for Accessible Medicines (AAM), biosimilar and generic prescriptions account for 90% of the total prescriptions filled in the United States. Furthermore, the biosimilar and generic drugs generated USD 408 billion for the American healthcare system and its patients in 2022. This growth of biosimilar and generic drugs, is in turn, positively influencing the expansion of the market. Additionally, the rising prevalence of several genetic disorders, chronic diseases, and infectious diseases in various regions across the globe are propelling the requirement for safe and effective medications, thus bolstering the demand for pharmaceutical contract manufacturing as they aid in providing quality-assured products in a cost-efficient manner.

Future Market Scenario (2024-2031F)

According to the global pharmaceutical contract manufacturing market analysis, contract manufacturing is expected to play a significant role in the pharmaceutical industry in the coming years, and the integration of novel technologies, such as machine learning and artificial intelligence, is anticipated to aid in enhancing the operations of pharmaceutical contract manufacturing. The deployment of real-time monitoring solutions due to the advent of the Internet of Things (IoT) for ensuring that the quality is maintained during the production process and response is generated for any issues in a time-efficient manner is expected to enhance the reliability and efficiency of the supply chain in pharmaceutical contract manufacturing.

Key Players Landscape and Outlook

Successful mergers and acquisitions are expected to boost the global pharmaceutical contract manufacturing market size. In February 2024, Novo Holdings A/S and Catalent, Inc. announced that they have entered into a merger agreement, and Novo Holdings will be acquiring Catalent for USD 16.5 billion. Novo Holdings will be transferring Catalent's manufacturing sites to Novo Nordisk A/S to boost their efforts to meet the growing demand for their injectable obesity and semaglutide-based diabetes drugs Wegovy and Ozempic. The acquired sites are expected to aid the company's filling capacity from 2026. This investment is expected to aid Novo Nordisk in enhancing its key product offerings and providing premium manufacturing and development solutions to biotech and pharma customers.

The increase in investments by the key market players in drug production facilities is also expected to bolster the growth of the market. In May 2023, Thermo Fisher Scientific Inc. opened a drug production facility in Singapore. The facility is expected to support the company's general manufacturing and development services and the Singapore Economic Development Board (EDB). The sterile fill-finish facility contains an automated aseptic fill-finish line with advanced isolator technology for small and large-sized molecules and vaccines.

Table of Contents

1. Research Methodology

2. Project Scope & Definitions

3. Executive Summary

4. Global Pharmaceutical Contract Manufacturing Market Outlook, 2017-2031F

  • 4.1. Market Size & Forecast
    • 4.1.1. By Value
  • 4.2. By Service
    • 4.2.1. Pharmaceutical Manufacturing Services
      • 4.2.1.1. Pharmaceutical FDF Manufacturing Services
      • 4.2.1.2. Pharmaceutical API Manufacturing Services
    • 4.2.2. Biologic Manufacturing Services
      • 4.2.2.1. Biologic FDF Manufacturing Services
      • 4.2.2.2. Biologic API Manufacturing Services
    • 4.2.3. Drug Development Services
  • 4.3. By Dosage Form
    • 4.3.1. Oral Solids
    • 4.3.2. Oral Liquid
    • 4.3.3. Emulsions
    • 4.3.4. Parenteral
    • 4.3.5. Others
  • 4.4. By End-user
    • 4.4.1. Big Pharmaceutical Companies
    • 4.4.2. Small and Mid-Sized Pharmaceutical Companies
    • 4.4.3. Generic Pharmaceutical Companies
    • 4.4.4. Others
  • 4.5. By Region
    • 4.5.1. North America
    • 4.5.2. South America
    • 4.5.3. Europe
    • 4.5.4. Asia-Pacific
    • 4.5.5. Middle East & Africa
  • 4.6. By Company Market Share (%), 2023

5. Global Pharmaceutical Contract Manufacturing Market Outlook, By Region, 2017-2031F

  • 5.1. North America*
    • 5.1.1. Market Size & Forecast
      • 5.1.1.1. By Value
    • 5.1.2. By Service
      • 5.1.2.1. Pharmaceutical Manufacturing Services
        • 5.1.2.1.1. Pharmaceutical FDF Manufacturing Services
        • 5.1.2.1.2. Pharmaceutical API Manufacturing Services
      • 5.1.2.2. Biologic Manufacturing Services
        • 5.1.2.2.1. Biologic FDF Manufacturing Services
        • 5.1.2.2.2. Biologic API Manufacturing Services
      • 5.1.2.3. Drug Development Services
    • 5.1.3. By Dosage Form
      • 5.1.3.1. Oral Solids
      • 5.1.3.2. Oral Liquid
      • 5.1.3.3. Emulsions
      • 5.1.3.4. Parenteral
      • 5.1.3.5. Others
    • 5.1.4. By End-user
      • 5.1.4.1. Big Pharmaceutical Companies
      • 5.1.4.2. Small and Mid-Sized Pharmaceutical Companies
      • 5.1.4.3. Generic Pharmaceutical Companies
      • 5.1.4.4. Others
    • 5.1.5. United States*
      • 5.1.5.1. Market Size & Forecast
        • 5.1.5.1.1. By Value
      • 5.1.5.2. By Service
        • 5.1.5.2.1. Pharmaceutical Manufacturing Services
          • 5.1.5.2.1.1. Pharmaceutical FDF Manufacturing Services
          • 5.1.5.2.1.2. Pharmaceutical API Manufacturing Services
        • 5.1.5.2.2. Biologic Manufacturing Services
          • 5.1.5.2.2.1. Biologic FDF Manufacturing Services
          • 5.1.5.2.2.2. Biologic API Manufacturing Services
        • 5.1.5.2.3. Drug Development Services
      • 5.1.5.3. By Dosage Form
        • 5.1.5.3.1. Oral Solids
        • 5.1.5.3.2. Oral Liquid
        • 5.1.5.3.3. Emulsions
        • 5.1.5.3.4. Parenteral
        • 5.1.5.3.5. Others
      • 5.1.5.4. By End-user
        • 5.1.5.4.1. Big Pharmaceutical Companies
        • 5.1.5.4.2. Small and Mid-Sized Pharmaceutical Companies
        • 5.1.5.4.3. Generic Pharmaceutical Companies
        • 5.1.5.4.4. Others
    • 5.1.6. Canada
    • 5.1.7. Mexico

All segments will be provided for all regions and countries covered

  • 5.2. Europe
    • 5.2.1. Germany
    • 5.2.2. France
    • 5.2.3. Italy
    • 5.2.4. United Kingdom
    • 5.2.5. Russia
    • 5.2.6. Netherlands
    • 5.2.7. Spain
    • 5.2.8. Turkey
    • 5.2.9. Poland
  • 5.3. Asia-Pacific
    • 5.3.1. India
    • 5.3.2. China
    • 5.3.3. Japan
    • 5.3.4. Australia
    • 5.3.5. Vietnam
    • 5.3.6. South Korea
    • 5.3.7. Indonesia
    • 5.3.8. Philippines
  • 5.4. South America
    • 5.4.1. Brazil
    • 5.4.2. Argentina
  • 5.5. Middle East & Africa
    • 5.5.1. Saudi Arabia
    • 5.5.2. UAE
    • 5.5.3. South Africa

6. Market Mapping, 2023

  • 6.1. By Service
  • 6.2. By Dosage Form
  • 6.3. By End-user
  • 6.4. By Region

7. Macro Environment and Industry Structure

  • 7.1. Supply Demand Analysis
  • 7.2. Import Export Analysis
  • 7.3. Value Chain Analysis
  • 7.4. PESTEL Analysis
    • 7.4.1. Political Factors
    • 7.4.2. Economic System
    • 7.4.3. Social Implications
    • 7.4.4. Technological Advancements
    • 7.4.5. Environmental Impacts
    • 7.4.6. Legal Compliances and Regulatory Policies (Statutory Bodies Included)
  • 7.5. Porter's Five Forces Analysis
    • 7.5.1. Supplier Power
    • 7.5.2. Buyer Power
    • 7.5.3. Substitution Threat
    • 7.5.4. Threat from New Entrant
    • 7.5.5. Competitive Rivalry

8. Market Dynamics

  • 8.1. Growth Drivers
  • 8.2. Growth Inhibitors (Challenges and Restraints)

9. Regulatory Framework and Innovation

  • 9.1. Patent Landscape
  • 9.2. Regulatory Approvals
  • 9.3. Innovations/Emerging Technologies

10. Key Players Landscape

  • 10.1. Competition Matrix of Top Five Market Leaders
  • 10.2. Market Revenue Analysis of Top Five Market Leaders (in %, 2023)
  • 10.3. Mergers and Acquisitions/Joint Ventures (If Applicable)
  • 10.4. SWOT Analysis (For Five Market Players)
  • 10.5. Patent Analysis (If Applicable)

11. Pricing Analysis

12. Case Studies

13. Key Players Outlook

  • 13.1. Thermo Fisher Scientific Inc.
    • 13.1.1. Company Details
    • 13.1.2. Key Management Personnel
    • 13.1.3. Products & Services
    • 13.1.4. Financials (As reported)
    • 13.1.5. Key Market Focus & Geographical Presence
    • 13.1.6. Recent Developments
  • 13.2. Abbvie Inc.
  • 13.3. Lonza Group Ltd.
  • 13.4. Boehringer Ingelheim International GmbH
  • 13.5. Catalent, Inc.
  • 13.6. Pfizer, Inc.
  • 13.7. Evonik Industries AG
  • 13.8. Dr. Reddy's Laboratories Ltd.
  • 13.9. Jubilant Pharmova Limited
  • 13.10. Recipharm AB

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work

14. Strategic Recommendations

15. About Us & Disclaimer

List of Tables

  • Table 1. Pricing Analysis of Products from Key Players
  • Table 2. Competition Matrix of Top 5 Market Leaders
  • Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
  • Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

  • Figure 1. Global Pharmaceutical Contract Manufacturing Market, By Value, In USD Billion, 2017-2031F
  • Figure 2. Global Pharmaceutical Contract Manufacturing Market Share (%), By Service, 2017-2031F
  • Figure 3. Global Pharmaceutical Contract Manufacturing Market Share (%), By Dosage Form, 2017-2031F
  • Figure 4. Global Pharmaceutical Contract Manufacturing Market Share (%), By End-user, 2017-2031F
  • Figure 5. Global Pharmaceutical Contract Manufacturing Market Share (%), By Region, 2017-2031F
  • Figure 6. North America Pharmaceutical Contract Manufacturing Market, By Value, In USD Billion, 2017-2031F
  • Figure 7. North America Pharmaceutical Contract Manufacturing Market Share (%), By Service, 2017-2031F
  • Figure 8. North America Pharmaceutical Contract Manufacturing Market Share (%), By Dosage Form, 2017-2031F
  • Figure 9. North America Pharmaceutical Contract Manufacturing Market Share (%), By End-user, 2017-2031F
  • Figure 10. North America Pharmaceutical Contract Manufacturing Market Share (%), By Country, 2017-2031F
  • Figure 11. United States Pharmaceutical Contract Manufacturing Market, By Value, In USD Billion, 2017-2031F
  • Figure 12. United States Pharmaceutical Contract Manufacturing Market Share (%), By Service, 2017-2031F
  • Figure 13. United States Pharmaceutical Contract Manufacturing Market Share (%), By Dosage Form, 2017-2031F
  • Figure 14. United States Pharmaceutical Contract Manufacturing Market Share (%), By End-user, 2017-2031F
  • Figure 15. Canada Pharmaceutical Contract Manufacturing Market, By Value, In USD Billion, 2017-2031F
  • Figure 16. Canada Pharmaceutical Contract Manufacturing Market Share (%), By Service, 2017-2031F
  • Figure 17. Canada Pharmaceutical Contract Manufacturing Market Share (%), By Dosage Form, 2017-2031F
  • Figure 18. Canada Pharmaceutical Contract Manufacturing Market Share (%), By End-user, 2017-2031F
  • Figure 19. Mexico Pharmaceutical Contract Manufacturing Market, By Value, In USD Billion, 2017-2031F
  • Figure 20. Mexico Pharmaceutical Contract Manufacturing Market Share (%), By Service, 2017-2031F
  • Figure 21. Mexico Pharmaceutical Contract Manufacturing Market Share (%), By Dosage Form, 2017-2031F
  • Figure 22. Mexico Pharmaceutical Contract Manufacturing Market Share (%), By End-user, 2017-2031F
  • Figure 23. Europe Pharmaceutical Contract Manufacturing Market, By Value, In USD Billion, 2017-2031F
  • Figure 24. Europe Pharmaceutical Contract Manufacturing Market Share (%), By Service, 2017-2031F
  • Figure 25. Europe Pharmaceutical Contract Manufacturing Market Share (%), By Dosage Form, 2017-2031F
  • Figure 26. Europe Pharmaceutical Contract Manufacturing Market Share (%), By End-user, 2017-2031F
  • Figure 27. Europe Pharmaceutical Contract Manufacturing Market Share (%), By Country, 2017-2031F
  • Figure 28. Germany Pharmaceutical Contract Manufacturing Market, By Value, In USD Billion, 2017-2031F
  • Figure 29. Germany Pharmaceutical Contract Manufacturing Market Share (%), By Service, 2017-2031F
  • Figure 30. Germany Pharmaceutical Contract Manufacturing Market Share (%), By Dosage Form, 2017-2031F
  • Figure 31. Germany Pharmaceutical Contract Manufacturing Market Share (%), By End-user, 2017-2031F
  • Figure 32. France Pharmaceutical Contract Manufacturing Market, By Value, In USD Billion, 2017-2031F
  • Figure 33. France Pharmaceutical Contract Manufacturing Market Share (%), By Service, 2017-2031F
  • Figure 34. France Pharmaceutical Contract Manufacturing Market Share (%), By Dosage Form, 2017-2031F
  • Figure 35. France Pharmaceutical Contract Manufacturing Market Share (%), By End-user, 2017-2031F
  • Figure 36. Italy Pharmaceutical Contract Manufacturing Market, By Value, In USD Billion, 2017-2031F
  • Figure 37. Italy Pharmaceutical Contract Manufacturing Market Share (%), By Service, 2017-2031F
  • Figure 38. Italy Pharmaceutical Contract Manufacturing Market Share (%), By Dosage Form, 2017-2031F
  • Figure 39. Italy Pharmaceutical Contract Manufacturing Market Share (%), By End-user, 2017-2031F
  • Figure 40. United Kingdom Pharmaceutical Contract Manufacturing Market, By Value, In USD Billion, 2017-2031F
  • Figure 41. United Kingdom Pharmaceutical Contract Manufacturing Market Share (%), By Service, 2017-2031F
  • Figure 42. United Kingdom Pharmaceutical Contract Manufacturing Market Share (%), By Dosage Form, 2017-2031F
  • Figure 43. United Kingdom Pharmaceutical Contract Manufacturing Market Share (%), By End-user, 2017-2031F
  • Figure 44. Russia Pharmaceutical Contract Manufacturing Market, By Value, In USD Billion, 2017-2031F
  • Figure 45. Russia Pharmaceutical Contract Manufacturing Market Share (%), By Service, 2017-2031F
  • Figure 46. Russia Pharmaceutical Contract Manufacturing Market Share (%), By Dosage Form, 2017-2031F
  • Figure 47. Russia Pharmaceutical Contract Manufacturing Market Share (%), By End-user, 2017-2031F
  • Figure 48. Netherlands Pharmaceutical Contract Manufacturing Market, By Value, In USD Billion, 2017-2031F
  • Figure 49. Netherlands Pharmaceutical Contract Manufacturing Market Share (%), By Service, 2017-2031F
  • Figure 50. Netherlands Pharmaceutical Contract Manufacturing Market Share (%), By Dosage Form, 2017-2031F
  • Figure 51. Netherlands Pharmaceutical Contract Manufacturing Market Share (%), By End-user, 2017-2031F
  • Figure 52. Spain Pharmaceutical Contract Manufacturing Market, By Value, In USD Billion, 2017-2031F
  • Figure 53. Spain Pharmaceutical Contract Manufacturing Market Share (%), By Service, 2017-2031F
  • Figure 54. Spain Pharmaceutical Contract Manufacturing Market Share (%), By Dosage Form, 2017-2031F
  • Figure 55. Spain Pharmaceutical Contract Manufacturing Market Share (%), By End-user, 2017-2031F
  • Figure 56. Turkey Pharmaceutical Contract Manufacturing Market, By Value, In USD Billion, 2017-2031F
  • Figure 57. Turkey Pharmaceutical Contract Manufacturing Market Share (%), By Service, 2017-2031F
  • Figure 58. Turkey Pharmaceutical Contract Manufacturing Market Share (%), By Dosage Form, 2017-2031F
  • Figure 59. Turkey Pharmaceutical Contract Manufacturing Market Share (%), By End-user, 2017-2031F
  • Figure 60. Poland Pharmaceutical Contract Manufacturing Market, By Value, In USD Billion, 2017-2031F
  • Figure 61. Poland Pharmaceutical Contract Manufacturing Market Share (%), By Service, 2017-2031F
  • Figure 62. Poland Pharmaceutical Contract Manufacturing Market Share (%), By Dosage Form, 2017-2031F
  • Figure 63. Poland Pharmaceutical Contract Manufacturing Market Share (%), By End-user, 2017-2031F
  • Figure 64. South America Pharmaceutical Contract Manufacturing Market, By Value, In USD Billion, 2017-2031F
  • Figure 65. South America Pharmaceutical Contract Manufacturing Market Share (%), By Service, 2017-2031F
  • Figure 66. South America Pharmaceutical Contract Manufacturing Market Share (%), By Dosage Form, 2017-2031F
  • Figure 67. South America Pharmaceutical Contract Manufacturing Market Share (%), By End-user, 2017-2031F
  • Figure 68. South America Pharmaceutical Contract Manufacturing Market Share (%), By Country, 2017-2031F
  • Figure 69. Brazil Pharmaceutical Contract Manufacturing Market, By Value, In USD Billion, 2017-2031F
  • Figure 70. Brazil Pharmaceutical Contract Manufacturing Market Share (%), By Service, 2017-2031F
  • Figure 71. Brazil Pharmaceutical Contract Manufacturing Market Share (%), By Dosage Form, 2017-2031F
  • Figure 72. Brazil Pharmaceutical Contract Manufacturing Market Share (%), By End-user, 2017-2031F
  • Figure 73. Argentina Pharmaceutical Contract Manufacturing Market, By Value, In USD Billion, 2017-2031F
  • Figure 74. Argentina Pharmaceutical Contract Manufacturing Market Share (%), By Service, 2017-2031F
  • Figure 75. Argentina Pharmaceutical Contract Manufacturing Market Share (%), By Dosage Form, 2017-2031F
  • Figure 76. Argentina Pharmaceutical Contract Manufacturing Market Share (%), By End-user, 2017-2031F
  • Figure 77. Asia-Pacific Pharmaceutical Contract Manufacturing Market, By Value, In USD Billion, 2017-2031F
  • Figure 78. Asia-Pacific Pharmaceutical Contract Manufacturing Market Share (%), By Service, 2017-2031F
  • Figure 79. Asia-Pacific Pharmaceutical Contract Manufacturing Market Share (%), By Dosage Form, 2017-2031F
  • Figure 80. Asia-Pacific Pharmaceutical Contract Manufacturing Market Share (%), By End-user, 2017-2031F
  • Figure 81. Asia-Pacific Pharmaceutical Contract Manufacturing Market Share (%), By Country, 2017-2031F
  • Figure 82. India Pharmaceutical Contract Manufacturing Market, By Value, In USD Billion, 2017-2031F
  • Figure 83. India Pharmaceutical Contract Manufacturing Market Share (%), By Service, 2017-2031F
  • Figure 84. India Pharmaceutical Contract Manufacturing Market Share (%), By Dosage Form, 2017-2031F
  • Figure 85. India Pharmaceutical Contract Manufacturing Market Share (%), By End-user, 2017-2031F
  • Figure 86. China Pharmaceutical Contract Manufacturing Market, By Value, In USD Billion, 2017-2031F
  • Figure 87. China Pharmaceutical Contract Manufacturing Market Share (%), By Service, 2017-2031F
  • Figure 88. China Pharmaceutical Contract Manufacturing Market Share (%), By Dosage Form, 2017-2031F
  • Figure 89. China Pharmaceutical Contract Manufacturing Market Share (%), By End-user, 2017-2031F
  • Figure 90. Japan Pharmaceutical Contract Manufacturing Market, By Value, In USD Billion, 2017-2031F
  • Figure 91. Japan Pharmaceutical Contract Manufacturing Market Share (%), By Service, 2017-2031F
  • Figure 92. Japan Pharmaceutical Contract Manufacturing Market Share (%), By Dosage Form, 2017-2031F
  • Figure 93. Japan Pharmaceutical Contract Manufacturing Market Share (%), By End-user, 2017-2031F
  • Figure 94. Australia Pharmaceutical Contract Manufacturing Market, By Value, In USD Billion, 2017-2031F
  • Figure 95. Australia Pharmaceutical Contract Manufacturing Market Share (%), By Service, 2017-2031F
  • Figure 96. Australia Pharmaceutical Contract Manufacturing Market Share (%), By Dosage Form, 2017-2031F
  • Figure 97. Australia Pharmaceutical Contract Manufacturing Market Share (%), By End-user, 2017-2031F
  • Figure 98. Vietnam Pharmaceutical Contract Manufacturing Market, By Value, In USD Billion, 2017-2031F
  • Figure 99. Vietnam Pharmaceutical Contract Manufacturing Market Share (%), By Service, 2017-2031F
  • Figure 100. Vietnam Pharmaceutical Contract Manufacturing Market Share (%), By Dosage Form, 2017-2031F
  • Figure 101. Vietnam Pharmaceutical Contract Manufacturing Market Share (%), By End-user, 2017-2031F
  • Figure 102. South Korea Pharmaceutical Contract Manufacturing Market, By Value, In USD Billion, 2017-2031F
  • Figure 103. South Korea Pharmaceutical Contract Manufacturing Market Share (%), By Service, 2017-2031F
  • Figure 104. South Korea Pharmaceutical Contract Manufacturing Market Share (%), By Dosage Form, 2017-2031F
  • Figure 105. South Korea Pharmaceutical Contract Manufacturing Market Share (%), By End-user, 2017-2031F
  • Figure 106. Indonesia Pharmaceutical Contract Manufacturing Market, By Value, In USD Billion, 2017-2031F
  • Figure 107. Indonesia Pharmaceutical Contract Manufacturing Market Share (%), By Service, 2017-2031F
  • Figure 108. Indonesia Pharmaceutical Contract Manufacturing Market Share (%), By Dosage Form, 2017-2031F
  • Figure 109. Indonesia Pharmaceutical Contract Manufacturing Market Share (%), By End-user, 2017-2031F
  • Figure 110. Philippines Pharmaceutical Contract Manufacturing Market, By Value, In USD Billion, 2017-2031F
  • Figure 111. Philippines Pharmaceutical Contract Manufacturing Market Share (%), By Service, 2017-2031F
  • Figure 112. Philippines Pharmaceutical Contract Manufacturing Market Share (%), By Dosage Form, 2017-2031F
  • Figure 113. Philippines Pharmaceutical Contract Manufacturing Market Share (%), By End-user, 2017-2031F
  • Figure 114. Middle East & Africa Pharmaceutical Contract Manufacturing Market, By Value, In USD Billion, 2017-2031F
  • Figure 115. Middle East & Africa Pharmaceutical Contract Manufacturing Market Share (%), By Service, 2017-2031F
  • Figure 116. Middle East & Africa Pharmaceutical Contract Manufacturing Market Share (%), By Dosage Form, 2017-2031F
  • Figure 117. Middle East & Africa Pharmaceutical Contract Manufacturing Market Share (%), By End-user, 2017-2031F
  • Figure 118. Middle East & Africa Pharmaceutical Contract Manufacturing Market Share (%), By Country, 2017-2031F
  • Figure 119. Saudi Arabia Pharmaceutical Contract Manufacturing Market, By Value, In USD Billion, 2017-2031F
  • Figure 120. Saudi Arabia Pharmaceutical Contract Manufacturing Market Share (%), By Service, 2017-2031F
  • Figure 121. Saudi Arabia Pharmaceutical Contract Manufacturing Market Share (%), By Dosage Form, 2017-2031F
  • Figure 122. Saudi Arabia Pharmaceutical Contract Manufacturing Market Share (%), By End-user, 2017-2031F
  • Figure 123. UAE Pharmaceutical Contract Manufacturing Market, By Value, In USD Billion, 2017-2031F
  • Figure 124. UAE Pharmaceutical Contract Manufacturing Market Share (%), By Service, 2017-2031F
  • Figure 125. UAE Pharmaceutical Contract Manufacturing Market Share (%), By Dosage Form, 2017-2031F
  • Figure 126. UAE Pharmaceutical Contract Manufacturing Market Share (%), By End-user, 2017-2031F
  • Figure 127. South Africa Pharmaceutical Contract Manufacturing Market, By Value, In USD Billion, 2017-2031F
  • Figure 128. South Africa Pharmaceutical Contract Manufacturing Market Share (%), By Service, 2017-2031F
  • Figure 129. South Africa Pharmaceutical Contract Manufacturing Market Share (%), By Dosage Form, 2017-2031F
  • Figure 130. South Africa Pharmaceutical Contract Manufacturing Market Share (%), By End-user, 2017-2031F
  • Figure 131. By Service Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 132. By Dosage Form Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 133. By End-user Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 134. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023